239 completed. 239 Phase 3, 16 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 239 | Completed 239 |
| Phase 2 | 16 | Completed 16 |
Follow Hemostatic Disorders: new trials by email Literature Review of Hemostatic Disorders trials Research Report on Hemostatic Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz) Pazopanib, Placebo oral capsule - Hereditary Hemorrhagic Telangiectasia, Epistaxis | Phase 2 / Phase 3 | Completed | Cure HHT | 71 | 2023-05-08 | 2026-10-27 |
| Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma Isatuximab, Lenalidomide, Bortezomib - Multiple Myeloma | Phase 3 | Completed | University of Heidelberg Medical Center | 514 | 2023-04-14 | 2026-02-18 |
| Fibrinogen Early In Severe Trauma StudY II Fibrinogen Concentrate, Cryoprecipitate - Trauma, Haemorrhagic Shock | Phase 3 | Completed | Australian and New Zealand Intensive Care Research Centre | 900 | 2022-11-21 | 2026-09-09 |
| Evaluation of Glucocorticoids Plus Rituximab in Patients With Newly-Diagnosed or Relapsing IgA Vasculitis Rituximab Injection, placebo - IgA Vasculitis | Phase 3 | Completed | Hopital Foch | 75 | 2022-03-11 | 2026-06-11 |
| Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy - Multiple Myeloma | Phase 3 | Completed | National Cancer Institute (NCI) | 1 | 2022-02-16 | 2025-05-23 |
| Evaluation of a Transfusion Therapy Using Whole Blood in the Management of Coagulopathy in Patients With Acute Traumatic Hemorrhage Whole blood transfusion, Fractionated blood products transfusion - Trauma, Acute Hemorrhage | Phase 3 | Completed | Direction Centrale du Service de Santé des Armées | 200 | 2021-12-04 | 2026-01-26 |
| Safety and Feasibility of Argatroban As Anticoagulant in Adults with ECMO Argatroban, Unfractionated heparin - Extracorporeal Membrane Oxygenation Complication, Anticoagulants and Bleeding Disorders | Phase 2 / Phase 3 | Completed | Medical University of Vienna | 40 | 2021-12-01 | 2024-09-19 |
| A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) SVd (Selinexor+Bortezomib+dexamethasone), Vd (Bortezomib+dexamethasone) - Relapsed or Refractory Multiple Myeloma | Phase 3 | Completed | Antengene Corporation | 154 | 2021-07-12 | 2026-08-10 |
| Study to Evaluate the Efficacy and Safety of Valoctocogene Roxaparvovec, With Prophylactic Steroids in Hemophilia A valoctocogene roxaparvovec - Hemophilia A | Phase 3 | Completed | BioMarin Pharmaceutical | 22 | 2020-12-08 | 2025-10-08 |
| Hamburg Edoxaban for Anticoagulation in COVID-19 Study Anticoagulation Agents (Edoxaban and/or high dose LMWH), Low dose Low molecular weight heparin or Placebo - Covid19 | Phase 3 | Completed | Universitätsklinikum Hamburg-Eppendorf | 140 | 2020-11-12 | 2023-05-23 |
| A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care as a Rapid Response to (SARS-CoV-2) COVID-19 Pandemic Therapeutic anticoagulation - COVID, Coronavirus Infection | Phase 3 | Completed | University of Sao Paulo General Hospital | 465 | 2020-07-04 | 2021-10-26 |
| Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care Therapeutic Anticoagulation - COVID-19 | Phase 3 | Completed | Unity Health Toronto | 465 | 2020-05-11 | 2025-01-30 |
| Prospective Comparison of 18F-choline PET/CT and 18F-FDG PET/CT in the Initial Work-up of Multiple Myeloma Positron Emission Tomography using 18F-FCH, Positron Emission Tomography using 18F-FDG - Myeloma Multiple | Phase 3 | Completed | University Hospital, Bordeaux | 20 | 2019-11-12 | 2026-05-12 |
| Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy Daratumumab SC in combination with Lenalidomide, Lenalidomide PO (25mg), Dexamethasone PO (20mg): days 1, 8, 15, 22 of each 28-day cycle, until progression - Multiple Myeloma | Phase 3 | Completed | University Hospital, Lille | 294 | 2019-10-17 | 2026-09-23 |
| A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma Carfilzomib, Lenalidomide, Dexamethasone - Relapsed or Refractory Multiple Myeloma | Phase 3 | Completed | Amgen | 454 | 2019-05-08 | 2024-08-13 |
| A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant Daratumumab, Lenalidomide - Multiple Myeloma | Phase 3 | Completed | Janssen Research & Development, LLC | 200 | 2019-04-26 | 2026-06-23 |
| Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) bb2121, Daratumumab, Pomalidomide - Multiple Myeloma | Phase 3 | Completed | Celgene | 386 | 2019-04-16 | 2026-06-22 |
| TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma TJ202, Lenalidomide and Dexamethasone, Lenalidomide and Dexamethasone - Multiple Myeloma in Relapse, Refractory Multiple Myeloma | Phase 3 | Completed | TJ Biopharma Co., Ltd. | 289 | 2019-03-27 | 2024-07-03 |
| Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT) Ixazomib - Multiple Myeloma | Phase 3 | Completed | Millennium Pharmaceuticals, Inc. | 37 | 2019-01-24 | 2025-03-21 |
| A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy Daratumumab, Bortezomib, Lenalidomide - Multiple Myeloma | Phase 3 | Completed | Janssen Research & Development, LLC | 395 | 2018-11-06 | 2026-06-02 |
Showing 20 of 239. Sign in to see all of them.
Multiple Myeloma (197) · Neoplasms, Plasma Cell (47) · Lymphoma, Non-Hodgkin (30) · Hodgkin Disease (29) · Leukemia, Lymphocytic, Chronic, B-Cell (28) · Lymphoma (28) · Lymphoma, Large B-Cell, Diffuse (25) · Lymphoma, Mantle-Cell (25) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (25) · Lymphoma, B-Cell, Marginal Zone (24) · Lymphoma, Follicular (23) · Lymphoma, Large-Cell, Immunoblastic (23) · Recurrence (23) · Leukemia, Myeloid, Acute (22)
Hemic and Lymphatic Diseases (239) · Cardiovascular Diseases (238) · Vascular Diseases (238) · Hemorrhagic Disorders (235) · Hematologic Diseases (229) · Immune System Diseases (208) · Blood Protein Disorders (203) · Immunoproliferative Disorders (203) · Neoplasms by Histologic Type (203) · Paraproteinemias (202) · Lymphoproliferative Disorders (195) · Neoplasms (183) · Neoplasms, Plasma Cell (157) · Pathological Conditions, Signs and Symptoms (68)
Dexamethasone (78) · Bortezomib (47) · Lenalidomide (41) · Thalidomide (33) · Melphalan (27) · Cyclophosphamide (16) · Calcium Dobesilate (13) · Prednisone (13) · daratumumab (12) · carfilzomib (10) · Peripheral Blood Stem Cell Transplantation (9) · Doxorubicin (8) · Filgrastim (8) · ixazomib (8) · pomalidomide (8)
Amgen (13) · Celgene (13) · Janssen Research & Development, LLC (12) · Fred Hutchinson Cancer Center (7) · Millennium Pharmaceuticals, Inc. (7) · University of Arkansas (7) · Alliance for Clinical Trials in Oncology (6) · PETHEMA Foundation (6) · Bristol-Myers Squibb (5) · Fondazione EMN Italy Onlus (5) · Celgene Corporation (4) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (4) · Mayo Clinic (4) · National Cancer Institute (NCI) (4) · BioMarin Pharmaceutical (3)
United States (121) · France (62) · Germany (60) · Spain (53) · Canada (50) · United Kingdom (47) · Italy (46) · Belgium (42) · Australia (40) · Czechia (35) · Greece (34) · Poland (32) · Sweden (32) · Austria (31) · Israel (29)
Robert Knight, MD (6) · Mario Boccadoro, MD (4) · Mary Horowitz, MD (3) · Amine Bensmaine, MD (2) · Bart Barlogie, M.D., Ph.D. (2) · Brenda Sandmaier (2) · Chaim Shustik, MD (2) · David J. Straus, MD (2)
PMID 31221778, PMID 34289038, PMID 22689675, PMID 38023148, PMID 39229471, PMID 18799726, PMID 19901114, PMID 21160068, PMID 21228328, PMID 21273172, PMID 21791470, PMID 23065509, PMID 23233721, PMID 23897961, PMID 24117042, PMID 25261096, PMID 26771810, PMID 27002117, PMID 27738789, PMID 28293022, PMID 29675792, PMID 30561775, PMID 31221782, PMID 31231828, PMID 31248973, PMID 32499241, PMID 33513030, PMID 34268513, PMID 34269818, PMID 34587246, PMID 35876974, PMID 36108425, PMID 36130300, PMID 38031761, PMID 38048391, PMID 38048552, PMID 39293025, PMID 42085642, PMID 12401245, PMID 15459300, PMID 15968290, PMID 16224404, PMID 16365178, PMID 16404741, PMID 16419071, PMID 16432076, PMID 16505427, PMID 16525139, PMID 16530576, PMID 16710026
2014 (7), 2017 (7), 2005 (6), 2008 (4), 2018 (4), 2015 (3), 2016 (3), P30CA015083 (3), 2004 (2), 2009 (2), P30CA015704 (2), P30CA068485 (2), U01HL069294 (2), U10CA021115 (2), U10CA032102 (2)